Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lindsey Mangum

Physician Assistant, Medical Florence, AL Physician Assistant

NPI 1861631764 CMS profile 10976309

2129 Helton Dr, Florence, AL 35630

Open in the dashboard

General payments

$43,588

941 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lindsey Mangum of Florence, AL is reported in the CMS Open Payments database as having received $43,588 across 941 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,443 171
2024 General $7,320 193
2023 General $17,549 200
2022 General $6,631 202
2021 General $2,647 175

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lindsey Mangum
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Lindsey Mangum were reported at $9,443. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Lindsey Mangum Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,647 $156 $41–$563 $132
2022 $6,631 $185 $55–$649 $149
2023 $17,549 $199 $58–$717 $160
2024 $7,320 $206 $62–$740 $164
2025 $9,443 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $30,599 214 payments
  2. UCB, Inc. $1,411 105 payments
  3. SK Life Science, Inc. $1,177 70 payments
  4. Biogen, Inc. $1,082 70 payments
  5. Pfizer Inc. $751 54 payments
  6. Lilly USA, LLC $665 40 payments
  7. Neurocrine Biosciences, Inc. $553 23 payments
  8. Lundbeck LLC $517 24 payments
  9. Argenx US, Inc. $488 17 payments
  10. ACADIA Pharmaceuticals Inc $423 20 payments
  11. Other $5,923 304 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $27,713 29 payments
  2. Food and Beverage $15,192 899 payments
  3. Travel and Lodging $659 10 payments
  4. Education $24 3 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $27,855 172 payments
  2. QULIPTA $23,981 130 payments
  3. Briviact $1,126 93 payments
  4. TYSABRI $764 50 payments
  5. INGREZZA $553 23 payments
  6. NURTEC ODT Pain $511 44 payments
  7. VUMERITY $502 34 payments
  8. NURTEC ODT Primary Care $462 33 payments
  9. ZAVZPRET $428 37 payments
  10. Epidiolex $399 19 payments
  11. Other $8,823 438 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 87 drugs

Part D claims

6,137

Median for Physician Assistant: 241

Drug cost

$4,047,733

Median for Physician Assistant: $4,110

Branded share of claims

32.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 103 $1,226,155
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 71 $630,164
Nuplazid Pimavanserin Tartrate Brand 68 $325,829
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 42 $269,419
Panzyga Immun Glob G(Igg)-Ifas/Glycine Brand 11 $209,686
Rebif Rebidose Interferon Beta-1a/Albumin Brand 15 $157,196
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 13 $109,976
Nurtec Odt Rimegepant Sulfate Brand 56 $106,118
Ubrelvy Ubrogepant Brand 79 $102,325
Fycompa Perampanel Brand 78 $89,557

The 10 drugs with the highest cost, of 87 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$54,329

Medicare's payments for the services billed

Medicare patients

488

Average age 72

Services billed

841

293 women, 195 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 37%
Depression 36%
Ischemic heart disease 26%
Chronic kidney disease 24%
COPD 23%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 40 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$2,574 79 —
QULIPTA
$1,838 39 —
Briviact
$341 39 —
VYVGART
$222 — —
INGREZZA
$194 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 40 with Patron

Records

941 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record